Among these, 34 hotspot mutations such as CD209 R129 missense (4.0 %) in bladder cancer, MAGI1 Q421 insertion (0.8 %) and NR1H2 Q175 insertion (1.8 %) in breast cancer were not well investigated based on previous studies and are potentially novel targets (Additional file 8: Table S5). This evidence concerns the gene NR1H2 and breast cancer.